Wolverine Legal Status, FDA 503A Category, and Compounding Access
The access record read first: where BPC-157 and TB-500 sit under the FDA's 503A framework today, and the July 2026 advisory meeting whose votes FDA has not published. General information, not legal or medical advice.
Wolverine legal status: a July FDA review, no published result
The Wolverine legal status story drew real attention this year. The FDA's Pharmacy Compounding Advisory Committee (PCAC) met on July 23-24, 2026 with BPC-157 and TB-500 on its agenda as candidates for the 503A Bulks List, after FDA staff had proposed against adding them [11]. As of September 2026 FDA has posted no record of the committee's votes, so that meeting is the latest citable step on exactly these peptides, not an answer.
Attention is not a decision, though, and this review will not pretend otherwise. FDA's page, content current as of April 22, 2026, places both constituents in its "Bulk drug substances nominated but withdrawn" table after their nominators pulled the requests; the agency's safety concerns remain published, but FDA has not explained how a pharmacy should treat a withdrawn nomination [9][10]. The July meeting was a step in evaluation, not a listing; a PCAC discussion is advisory, and no outcome should be assumed or dated [10][11].
So the honest framing is hedged: the door was looked at in public, and FDA has not said what it found. What follows is the present-tense record, sourced to the FDA, with the July review marked as a meeting that took place and nothing more.
The current FDA 503A status of Wolverine's components
U.S. drug compounding is governed by two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally under a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulk drug substances list [10].
Under the FDA's interim policy, nominated substances were sorted into categories. Under that policy, FDA identified Category 2 substances as raising significant safety risks and said it might act against compounders that used them [10].
Wolverine's two ingredients are no longer in Category 2: FDA now places their withdrawn nominations in a separate table, retains the safety rationales for each, and has not explained what this altered listing means for a pharmacy [9]. Effective with the FDA's September 29, 2023 update to the nominated-substances list, the FDA placed BPC-157 in Category 2, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide impurities and active-ingredient characterization [9]. In the same update, the FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in Category 2, citing potential immunogenicity for certain routes and a lack of important safety information; the FDA's own list entry establishes that TB-500 is the LKKTETQ fragment associated with Thymosin Beta-4 [9]. Neither constituent is an FDA-approved drug, and FDA treats the two alike — both entered Category 2 in that update, and both now sit with the withdrawn nominations [9].
Both components went to one July review
There is no split between the two peptides at the regulatory level. Both BPC-157 and TB-500 were on the published agenda of the July 23-24, 2026 PCAC meeting, listed as bulk drug substances "being considered for inclusion on the 503A Bulks List" [11]. The agenda entries covered the free-base and acetate forms of each.
That single July review is the whole of the recent record this site will stand behind. Being discussed by PCAC is a step in evaluation — informed input that feeds FDA rulemaking — not a final listing decision [10][11]. No outcome has been published, and this review treats no change of status as done, dated, or certain.
The record now stops short of a final FDA answer: staff proposed against adding either constituent before the July 2026 meeting, FDA had published no committee vote record as of September 2026, and its pages do not spell out how withdrawal of the nominations bears on pharmacy compounding [9][11].
How legally compounded peptide access works
In general terms, a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [10]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility [10].
Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It is a route to a licensed-prescriber consultation, not a separate legal status: telehealth does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription [10].
The ingredient-eligibility caveat is the binding one here. A compounder may use a requested active ingredient only if it is eligible under the 503A/503B bulk-substance rules — a USP/NF monograph, a component of an approved drug, or a place on the applicable bulks list. While FDA held BPC-157 and TB-500 in Category 2, they fell outside routine 503A compounding; its current page shows both as withdrawn nominations and is silent on whether a pharmacy may use either one [9][10]. This page is general information about the regulatory landscape; it is not medical or legal advice, and it does not name or endorse any pharmacy, clinic, or provider.
Doping status
Beyond the compounding question, both constituents are prohibited in sport. The World Anti-Doping Agency lists BPC-157 under its S0 non-approved-substances category and lists TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories; the blend is banned for athletes subject to the Code. The TB-500 fragment was in fact synthesized and characterized as a doping-control reference, which fixes its identity for analytical testing [5].
Is Wolverine legal?
Neither constituent is an FDA-approved drug, and the blend has no approved therapeutic indication. FDA's April 22, 2026 page records that the nominations for BPC-157 and TB-500 (LKKTETQ) were withdrawn and still displays its safety concerns; FDA has not explained whether that changes a pharmacy's options [9][10]. Both are also prohibited in sport under the World Anti-Doping Code. This is general information, not legal advice.
Can you get BPC-157 from a compounding pharmacy?
There is no plain yes on the FDA record. The FDA placed BPC-157 in Category 2 in its September 29, 2023 list update; by the page current as of April 22, 2026, the nomination had been withdrawn, and FDA has not said how compounders should read that change [9]. BPC-157 was on the July 23-24, 2026 PCAC agenda as a candidate for the 503A Bulks List; FDA staff had argued against listing it, and FDA had released no vote record from that meeting as of September 2026 [11].
What is the FDA 503A status of Wolverine?
The FDA placed BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in Category 2 on September 29, 2023, citing significant safety risks; its current page instead records that both nominations were taken back, and FDA has not answered how pharmacies should apply that change [9]. Both were agenda items at the July 23-24, 2026 PCAC meeting as bulks-list candidates; FDA had announced no listing decision by September 2026 [11].
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is FDA-approved for human use, and the blend has no approved therapeutic indication. The FDA's September 29, 2023 update put both BPC-157 and the TB-500 (LKKTETQ) fragment into 503A Category 2 over significant safety risks; its page as of April 22, 2026 no longer shows either one in that category, because both nominations were withdrawn [9]. Both constituents are prohibited by WADA — BPC-157 under S0, and TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories [5].